The ADHD Child Care Guide, the Latest Free Report Available on Attention-Deficit Hyperactivity Disorder, Is Now Available at ADHDChildCare.com

Recently, the US FDA approved Daytrana , Shire's product for treating patients aged between 13 to 17 years suffering from Attention Deficit Hyperactivity Disorder .

Recently, the US FDA approved Daytrana , Shire's product for treating patients aged between 13 to 17 years suffering from Attention Deficit Hyperactivity Disorder .

Shire PLC said Tuesday that U.S. regulators approved its attention deficit hyperactivity disorder patch Daytrana for use in adolescents age 13 to 17.

Turning in assignments, following instructions and focusing on learning something new are among the daily classroom challenges for children with Attention Deficit Hyperactivity Disorder (ADHD),[1] according to the National Institute of Mental Health (NIMH). New data presented today show efficacy of CONCERTA� (OROS� methylphenidate HCl Extended-Release Tablets CII) on ADHD symptoms in children ...